Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 9/20 | 0.47 |
| ▸ | HTR2B | P41595 | 9/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.47 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | TACR3 | P29371 | 3/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251478 | 0.84 | LMNA (0.47) | LMNAHTTNPSR1L3MBTL1HTR2A | |
| SCHEMBL15700121 | 0.74 | LMNA (0.54) | LMNAHTTNPSR1L3MBTL1HTR2A | |
| SCHEMBL25517186 | 0.74 | TSHR (0.41) | TACR3TACR1MAPTCYP2C19 | |
| SCHEMBL12083295 | 0.73 | SIGMAR1 (0.50) | L3MBTL1HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL856934 | 0.72 | NPSR1 (0.46) | LMNAHTTNPSR1L3MBTL1MAPT | |
| SCHEMBL30645252 | 0.72 | NPSR1 (0.46) | LMNAHTTNPSR1L3MBTL1MAPT | |
| SCHEMBL1153942 | 0.72 | TACR3 (0.53) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL28463030 | 0.70 | DGAT1 (0.48) | L3MBTL1HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL10341542 | 0.70 | DGAT1 (0.60) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL1153103 | 0.69 | TACR3 (0.75) | SIGMAR1TACR3TACR1GPR119CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280779-B1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORP (FI) | 2005-08-24 | — | — | EP | disclosed |
| EP-1280779-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2003-02-05 | — | — | EP | disclosed |
| US-6362211-B2 | FOR THERAPY OF NEUROLOGICAL, PSYCHIATRIC OR COGNITION DISORDER, DIABETES, LIPOLYTIC DISORDER, ORTHOSTATIC HYPOTENSION, OR SEXUAL DYSFUNCTION | ORION CORPORATION (FI) | 2002-03-26 | — | — | US | disclosed |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ORION CORPORATION (FI) | 2002-01-31 | — | — | US | disclosed |
| WO-2001085698-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ADRB2, ADRB1, ADRA1A | LMNA 1844/4885HTT 4500/4885NPSR1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.